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Mapping epigenetic regulator gene mutations in
cytogenetically normal pediatric acute myeloid
leukemia
Acute myeloid leukemia (AML) accounts for approxi-
mately 15-20% of all childhood leukemias, and despite dra-
matic improvements in treatment outcome, only approxi-
mately 70% of children with AML are cured.1 AML results
from collaborating genetic aberrations in at least 2 different
classes; type-I aberrations, inducing uncontrolled cell prolif-
eration and/or survival, and type-II aberrations inhibiting
cell differentiation. However, certain aberrations found in
AML do not completely fit into our current definition of
type-I and type-II aberrations.2 These aberrations concern
epigenetic modifier genes involved in DNA methylation
and histone modification, such as Ten-Eleven Translocation
2 (TET2), Isocitrate Dehydrogenase 1 (IDH1), IDH2,
Enhancer of Zeste Homolog 2 (EZH2), DNA (cytosine-5)-
Methyltransferase 3 Alpha (DNMT3A) and Additional Sex
Combs Like-1 (ASXL1). Most of these genes are frequently
mutated in adult AML patients with a prevalence varying
between 12% to 35% per gene.3-7 Reports on prognostic
implications of these mutations are ambiguous. It has,
however, been shown that patients with IDH mutations
have a hypermethylation phenotype. This implies that
demethylating agents such as decitabine and azacytidine
may be of use in the treatment of IDH-mutated AML. In
addition, a favorable outcome in elderly AML patients with
DNMT3A mutations after treatment with decitabine has
been reported.7,8
These epigenetic regulator genes were also studied in
pediatric AML. Most of these studies focused on the rele-
vance of mutations in a single gene and mutations were
detected in 1-4% of the patients.9-13 Although no significant
statements can be made since study cohorts were quite
heterogeneous, most mutations seemed to occur in cytoge-
netically normal (CN) AML, a subgroup that comprises 20-
25% of all pediatric AML. This distribution corresponds to
adult AML data in which most epigenetic regulator gene
mutations were also identified in CN patients. So far, no
larger study focusing on pediatric CN-AML is available and
identifying these genetic aberrations may lead to improved
risk stratification and a rationale for the use of demethylat-
ing agents in these patients. Therefore, we decided to study
the mutation prevalence of epigenetic regulator genes
EZH2, IDH1/2, DNMT3A, ASXL1 and TET2 in a well-doc-
umented, international cohort of 65 de novo pediatric CN-
AML patients.
Patient material was obtained from the Dutch Childhood
Oncology Group (DCOG), the AML-Berlin-Frankfurt-
Münster Study group (AML-BFM), the Czech Pediatric
Hematology Group, and the Saint-Louis Hospital in Paris,
France. A minor selection of the discovered mutations had
been included in previous reports, but not with a focus on
CN-AML and never within one cohort.11-13 Exon 4 of
IDH1/2, exon 13 of ASXL1, the SET-domain of EZH2 and
the entire coding region of TET2 were screened using
Sanger sequencing of genomic DNA. The mutational status
of DNMT3A was assessed by screening cDNA and aberra-
tions were verified in genomic DNA. The prevalence of
cytogenetic and molecular aberrations was assessed as pre-
viously described.14 
In our study cohort, aberrations in the genes IDH1 and
IDH2 occurred with a frequency of 10.8% (95%CI ± 7.5%)
and mutations in TET2 and DNMT3A were found with a
frequency of 4.6% (95%CI ± 5.1%) each. While all aberra-
tions in IDH1 and IDH2 were confined to codon 132 and
140, respectively, various mutation loci were observed in
TET2 and DNMT3A. All epigenetic regulator gene muta-
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Table 1. Clinical and genetic characteristics of pediatric CN-AML cases carrying an epigenetic regulator gene mutation.
Gene Patient Mutation1 Protein Age Sex WBC Other Survival Months
change2 (yrs) count mutations status of follow up
(x109/uL)
IDH1 1 c.395G>A p.R132H 3.6 M 14.1 NUP98-NSD1; K-RAS Death after relapse 23
IDH1 2 c.395G>A p.R132H 14.3 F 44.8 FLT3-ITD; MLL-PTD Alive 50
IDH1 3 c.395G>A p.R132H 15.1 M 9.6 Alive 104
IDH1 4 c.394C>T p.R132C 12.6 F 3.0 Death after relapse 46
IDH1 5 c.395G>A p.R132H 13.0 M 226.0 NUP98-NSD1; FLT3-ITD Alive 32
IDH2 6 c.419G>A p.R140Q 7.5 M 120.4 MLL-PTD; FLT3-ITD Alive 71
IDH2 7 c.419G>A p.R140Q 6.0 M N/A NPM1; FLT3-ITD Alive 40
DNMT3A 8 c.2146G>T p.V716F 15.3 M 30.8 NPM1; N-RAS Alive 65
DNMT3A 9 c.2644C>T p.R882C 8.4 M 25.0 WT1; FLT3-ITD Alive 52
DNMT3A 10 c.1450C>T p.R484W 15.7 F 9.5 CEBPA dm Alive 6
TET2 11 c.3803+2_3ins T Unknown 11.1 F 163.0 NPM1; FLT3-ITD Alive 51
TET2 12 c.3646C>T p.R1216* 6.9 F 25.1 N-RAS Alive 50
c.4210C>T p.R1404*
TET2 13 c.1599G>A p.M533I 14.3 M 2.2 Alive 34
yrs: years; F: female; M: male; N/A: not available; WBC: white blood cell count; dm: double mutant. 1The nucleotide sequence variations are designated according to the recommen-
dations of the Human Genome Variation Society (HGVS, http:// www.hgvs.org/mutnomen/). Numbering of nucleotides is done by using the first base of the translated part of the
gene as nucleotide 1.Transcripts used as a reference are: NM_005896.2 for IDH1, NM_002168.2 for IDH2, NM_175629.2 for DNMT3A and NM_001127208.2 for TET2 (National
Center for Biotechnology Information). 2The protein changes are theoretically deduced and designated according to the recommendations of the HGVS. 
tions appeared to be mutually exclusive (Figure 1) and no
mutations were identified in EZH2 or ASXL1. The number
of patients with a mutation was too small to allow for sur-
vival analysis. The specifics of the identified aberrations
and the main clinical and genetic features of the patients
carrying an epigenetic regulator gene mutation are summa-
rized in Table 1. The epigenetic regulator gene mutations
co-occurred with well-known type-I/II aberrations (Figure
1). Out of 13 patients with 10 epigenetic regulator gene
mutation also carried a FLT3-ITD (n=6) or RAS mutation
(n=4), and 6 of 13 patients were found to have a CEBPA
double mutation (n=1), NPM1 mutation (n=3), or NUP98-
NSD1 translocation (n=2). Overall, epigenetic regulator
gene mutations were shown to co-exist with both a type-I
and type-II driver aberration in 7 of 13 patients. 
In this study of a substantial pediatric CN-AML cohort,
we have identified recurrent somatic mutations in the epi-
genetic regulator genes IDH1, IDH2, DNMT3A and TET2
in 13 of 65 cases (20%). IDH1/2mutations occurred signif-
icantly more often in pediatric CN-AML than in previously
reported pediatric AML cohorts with patients carrying var-
ious cytogenetic aberrations (P=0.025).12 Although the
aberration frequency of epigenetic regulator gene muta-
tions is relatively high for a pediatric AML cohort, the
prevalence is still evidently lower in pediatric CN-AML
than in adult CN-AML. In addition, within adult AML,
IDH2, ASXL1 and TET2 mutations are significantly more
prevalent in elderly patients, suggesting an increasing
prevalence of these mutations as a function of age.3,4,6 A
recent study from Welch et al. identified DNMT3A, IDH1/2,
TET2, ASXL1 and NPM1mutations as possible major initi-
ating or driver mutations in CN-AML, rather than co-oper-
ating events acquired at a later stage of clonal evolution.15
However, we found epigenetic regulator gene mutations in
only 20% of our pediatric CN-AML cohort, and in addition,
these mutations often co-occurred with other type-I/II
aberrations thought to have leukemia driving capabilities,
such as NUP98-NSD1 and NPM1. This suggests that there
might be other, as yet unidentified driver mutations in pedi-
atric AML, reflecting potential differences in pathophysiol-
ogy between childhood and adult AML. Future clonal evo-
lution studies of pediatric CN-AML might lead to a better
understanding of the initiating and co-operating events in
this disease.
Mutations in ASXL1 and EZH2 were absent in our pedi-
atric CN-AML cohort. This corresponds to literature
reports that ASXL1 and EZH2mutations in childhood AML
are very rare. EZH2 mutations seem to be highly uncom-
mon in pediatric as well as in adult AML, in contrast to the
high prevalence observed in other myeloid malignancies
such as adult myelodysplastic syndrome.5
In summary, we identified epigenetic regulator gene
mutations to be mutually exclusive and recurrent, but infre-
quent in pediatric CN-AML. IDH1/2 aberrations were more
frequent in pediatric CN-AML than in published series of
other cytogenetic AML subgroups. The frequency of epige-
netic regulator gene mutations is lower in pediatric than in
adult CN-AML which underlines the difference in patho-
physiology between the two. While there is currently insuf-
ficient solid rationale for routine screening of epigenetic
regulator gene mutations in newly diagnosed pediatric CN-
AML patients, new agents are emerging that may make
screening more therapeutically appealing. 
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Figure 1. Distribution of somatic mutations in 65 pediatric CN-AML patients. Patients are represented vertically (patient number 1 to num-
ber 65 from left to right, 1 column per patient) and molecular aberrations horizontally. Each mutated patient is represented by a colored
rectangle, a wild-type patient by a white rectangle and when data are not available due to lack of patient material, the rectangle is gray.
CEBPA is considered mutated in case of a double mutation only.
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